GHRP-2

Overview

GHRP-2 (pralmorelin) is a six-amino acid synthetic peptide that acts as a potent agonist at the growth hormone secretagogue receptor (GHSR-1a). It produces a strong and relatively dose-dependent spike in GH secretion and was the first GHRP to enter clinical trials for GH deficiency diagnostics. Compared to GHRP-6, it causes less pronounced appetite stimulation while maintaining similar or superior GH-releasing potency.

GHRP-2 also modestly increases cortisol and prolactin — less than GHRP-6 but more than ipamorelin — which is an important consideration in research protocols. It is often studied in combination with GHRH analogues like CJC-1295 or sermorelin for synergistic GH release.

Mechanism of Action

GHRP-2 binds to GHSR-1a receptors in the pituitary and hypothalamus, triggering intracellular calcium mobilization and PKC activation, which stimulates GH granule exocytosis. It also suppresses somatostatin tone in the hypothalamus, further amplifying GH release. Its ghrelin mimetic activity contributes to mild appetite stimulation.

Research Areas

• ●GH deficiency diagnostics and testing
• ●Appetite and energy regulation research
• ●GH/IGF-1 axis studies
• ●Lean mass and fat oxidation research
• ●Cardioprotective effects in animal models
• ●GH pulse amplification when combined with GHRH

Storage & Handling

For Research Use Only. This information is provided for educational and research purposes. GHRP-2 is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.